Search results
Showing 46 to 60 of 127 results for epilepsy
or problems sleeping. Benzos can be used for other conditions, such as epilepsy. Talk to your healthcare professional if this applies to...
Outcomes should include reduction in seizure frequency and improvement in the epilepsy seizure outcome scale, quality of life, reduction...
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
Awaiting development Reference number: GID-TA11069 Expected publication date: TBC
In development Reference number: GID-TA10664 Expected publication date: TBC
compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy? Focal seizures: carbamazepine, eslicarbazepine...
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
Health inequalities can be experienced by people grouped by a range of different factors.
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
Violent and aggressive behaviours in people with mental health problems (QS154)
This quality standard covers short-term prevention and management of violent and physically threatening behaviour among adults, children and young people with a mental health problem. It applies to settings where mental health, health and social care services are provided. This includes community settings and care received at home. It describes high-quality care in priority areas for improvement.
View quality statements for QS154Show all sections
Sections for QS154
- Quality statements
- Quality statement 1: Identifying triggers and warning signs
- Quality statement 2: Preventing and managing violent or aggressive behaviour
- Quality statement 3: Physical health during and after manual restraint
- Quality statement 4: Physical health after rapid tranquillisation
- Quality statement 5: Immediate post-incident debrief
- About this quality standard
Care and support of people growing older with learning disabilities (NG96)
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
recommendationsThe only cannabis-based medicinal product available for the treatment of epilepsy is epidyolex, which is licensed...
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
recommendationsThe only cannabis-based medicinal product available for the treatment of epilepsy is epidyolex, which is licensed...
Transcranial magnetic stimulation for auditory hallucinations (HTG555)
Evidence-based recommendations on transcranial magnetic stimulation for auditory hallucinations. This involves stimulating the brain with pulses of electromagnetic energy.
View recommendations for HTG555Show all sections